Over the past 12 months, 3 insiders at Adverum Biotechnologies, Inc. filed 7 open-market SEC Form 4 transactions on ADVM: 3 purchases worth $765K and 4 sales worth $4.6M. Insiders have been mixed over this period. The most recent filing was on Dec 8, 25.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 8, 25 | Laurent FischerCEO, PRESIDENT AND DIRECTOR | BUY | 117.6K | $4.31 | $507K |
| Dec 5, 25 | Laurent FischerCEO, PRESIDENT AND DIRECTOR | BUY | 11.1K | $4.24 | $47K |
| Dec 5, 25 | Peter SoparkarCHIEF OPERATING OFFICER | BUY | 50.0K | $4.22 | $211K |
| Dec 4, 25 | Braden Michael LeonardTenPercentOwner | SELL | 524.6K | $4.19 | $2.2M |
| Dec 3, 25 | Braden Michael LeonardTenPercentOwner | SELL | 222.9K | $4.17 | $930K |
| Dec 2, 25 | Braden Michael LeonardTenPercentOwner | SELL | 52.0K | $4.20 | $218K |
| Dec 1, 25 | Braden Michael LeonardTenPercentOwner | SELL | 300.0K | $4.20 | $1.3M |
| May 15, 25 | Laurent FischerCEO, PRESIDENT AND DIRECTOR | SELL | 9.1K | $2.00 | $18K |
| May 15, 25 | Setareh SeyedkazemiCHIEF DEVELOPMENT OFFICER | SELL | 924 | $2.00 | $2K |
| May 15, 25 | Peter SoparkarCHIEF OPERATING OFFICER | SELL | 3.0K | $2.00 | $6K |
| Apr 23, 25 | Braden Michael LeonardTenPercentOwner | BUY | 50.0K | $2.98 | $149K |
| Apr 22, 25 | Braden Michael LeonardTenPercentOwner | BUY | 300.0K | $3.00 | $900K |
| Apr 2, 25 | Braden Michael LeonardTenPercentOwner | BUY | 15.2K | $4.04 | $61K |
| Mar 31, 25 | Braden Michael LeonardTenPercentOwner | BUY | 19.6K | $4.38 | $86K |
| Mar 27, 25 | Braden Michael LeonardTenPercentOwner | BUY | 16.6K | $5.19 | $86K |
| Mar 26, 25 | Braden Michael LeonardTenPercentOwner | BUY | 20.4K | $5.04 | $103K |
| Mar 20, 25 | Braden Michael LeonardTenPercentOwner | BUY | 30.6K | $5.61 | $172K |
| Mar 19, 25 | Braden Michael LeonardTenPercentOwner | BUY | 25.0K | $4.94 | $124K |
| Mar 18, 25 | Braden Michael LeonardTenPercentOwner | BUY | 44.3K | $4.73 | $210K |
| Feb 28, 25 | Braden Michael LeonardTenPercentOwner | BUY | 85.1K | $4.60 | $391K |
| Feb 27, 25 | Braden Michael LeonardTenPercentOwner | BUY | 86.8K | $4.46 | $387K |
| Feb 26, 25 | Braden Michael LeonardTenPercentOwner | BUY | 164.9K | $4.01 | $661K |
| Jul 30, 24 | Braden Michael LeonardTenPercentOwner | BUY | 85.8K | $7.15 | $613K |
| Jul 18, 24 | Braden Michael LeonardTenPercentOwner | BUY | 80.7K | $9.11 | $735K |
| Jul 17, 24 | Braden Michael LeonardTenPercentOwner | BUY | 135.5K | $7.75 | $1.1M |
| Feb 7, 24 | Jr. Mark L. LupherDirector | BUY | 130.0K | $1.35 | $176K |
| Feb 7, 24 | James Paul ScopaDirector | BUY | 100.0K | $1.35 | $135K |
| Sep 15, 23 | Setareh SeyedkazemiChief Development Officer | SELL | 6.1K | $1.55 | $9K |
| Jun 7, 23 | Linda M RubinsteinChief Financial Officer | BUY | 100.0K | $1.45 | $145K |
| Mar 15, 23 | Laurent FischerCEO, President and Director | SELL | 41.2K | $0.78 | $32K |
| Mar 15, 23 | Brigit RileyChief Scientific Officer | SELL | 7.3K | $0.78 | $6K |
| Mar 15, 23 | Peter SoparkarChief Operating Officer | SELL | 13.4K | $0.78 | $10K |
| Sep 19, 22 | Richard BeckmanChief Medical Officer | SELL | 4.3K | $1.07 | $5K |
| Sep 19, 22 | Laurent FischerCEO, President and Director | SELL | 41.1K | $1.07 | $44K |
| Sep 19, 22 | Brigit RileyChief Scientific Officer | SELL | 7.3K | $1.07 | $8K |
| Sep 19, 22 | Setareh SeyedkazemiChief Development Officer | SELL | 6.1K | $1.07 | $6K |
| Sep 19, 22 | Peter SoparkarSee Remarks section | SELL | 13.3K | $1.07 | $14K |
| May 23, 22 | Setareh SeyedkazemiChief Development Officer | BUY | 20.0K | $0.84 | $17K |
| May 17, 22 | Richard BeckmanChief Medical Officer | BUY | 10.0K | $0.82 | $8K |
| May 17, 22 | Rupert D'souzaChief Financial Officer | BUY | 10.0K | $0.83 | $8K |
| May 16, 22 | Dawn SvoronosDirector | BUY | 30.0K | $0.85 | $26K |
| May 13, 22 | Rupert D'souzaChief Financial Officer | BUY | 10.0K | $0.86 | $9K |
| Apr 20, 22 | Laurent FischerCEO, President and Director | BUY | 25.0K | $1.11 | $28K |
| Apr 19, 22 | Peter SoparkarSee Remarks section | BUY | 21.8K | $1.14 | $25K |
| Dec 9, 21 | Laurent FischerCEO, President and Director | BUY | 14.3K | $1.85 | $26K |
| Dec 8, 21 | Laurent FischerCEO, President and Director | BUY | 10.7K | $1.79 | $19K |
| Dec 8, 21 | Peter SoparkarSee Remarks section | BUY | 25.0K | $1.91 | $48K |
| Nov 15, 21 | James Paul ScopaDirector | SELL | 50.0K | $2.18 | $109K |
| Sep 30, 21 | Julie ClarkChief Medical Officer | SELL | 4.8K | $2.17 | $10K |
Over the past 12 months, insiders at Adverum Biotechnologies, Inc. filed 3 open-market purchases worth $765K and 4 sales worth $4.6M on ADVM, which makes them mixed over the period. The most recent Form 4 was filed on Dec 8, 25.
The largest recent open-market ADVM insider purchase in our data was $1.1M by Braden Michael Leonard, TenPercentOwner, filed on Jul 17, 24.
3 different insiders at Adverum Biotechnologies, Inc. filed open-market SEC Form 4 transactions on ADVM over the last 12 months.
InsiderTape plots every ADVM insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Adverum Biotechnologies, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →